arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Passage BIO, Inc.

PASG

$4.45 ▼ -0.15 (-3.26%) at close

8 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Passage BIO, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $14.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -207.6% ↘

FCF / Share $-9.93 ↗

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-45.52M

↑ +29.7% —

FCF / Share Free cash flow per share

$-9.93

↑ +36.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	31.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	43.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	25.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	28.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-19.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	29.7% Excellent → Excellent Stable Year-over-year change in net income	36.5% Excellent ↑ Excellent Improving Year-over-year change in net income	25.0% Excellent ↑ Excellent Improving Year-over-year change in net income	26.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-65.2% Weak Weak Year-over-year change in net income	-145.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	36.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	45.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	34.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	8.7% Fair Fair Year-over-year change in free cash flow	-14.1% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF / Net Income (x)	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-207.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-90.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-76.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-54.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	52.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-79.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-68.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-72.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-52.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-20.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-242.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1718%)	-105.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-805%)	-91.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-711%)	-67.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-551%)	-58.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-488%)	-36.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-346%)	81.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+441%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-46.30M	$-37.57M	$-21.71M	$-34.60M	$-128.97M	$-135.00M	$-158.87M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-14.35	$-21.04	$-37.20	$-50.00	$-69.60	$-58.20	—	—
Free Cash Flow per Share (USD)	$-9.93	$-15.58	$-28.59	$-43.44	$-47.57	$-41.70	—	—
Book Value per Share (USD)	$5.89	$19.38	$40.51	$73.74	$117.49	$133.60	$-262.07	—
Tangible Book Value per Share (USD)	$5.89	$19.38	$40.51	$73.74	$117.49	$133.60	$-262.07	—
Basic Weighted Avg Shares (shares)	3.17M	3.08M	2.74M	2.72M	2.67M	1.93M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$24.68M	$59.45M	$101.62M	$178.69M	$295.57M	$296.01M	$162.09M	—
Total Equity (USD)	$18.75M	$61.26M	$111.28M	$201.37M	$318.66M	$304.71M	$-56.25M	$-12.17M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	$728.00K	$3.08M	$3.72M	$3.68M	$1.54M	$800.00K	$134.00K	—
Net Income, GAAP (USD)	$-45.52M	$-64.77M	$-102.06M	$-136.12M	$-185.39M	$-112.23M	$-45.63M	—
Operating Cash Flow (USD)	$-31.51M	$-47.96M	$-78.26M	$-118.21M	$-126.88M	$-80.52M	$-39.90M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Passage BIO, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PASG with peers